The rationale of pharmacoeconomic analysis in rheumatologic indications

Clinical and Experimental Rheumatology

Volumn 30, Issue 4 SUPPL.73, 2012, Pages

  Turchetti, G ^a   Scalone, L ^b,c   Della Casa Alberighi, O ^d   Mosca, M ^e   Montella, S ^f   Cortesi, P A ^b,c   Mantovani, L G ^g  

^a SCUOLA SUPERIORE SANT ANNA   (Italy)

^b Fondazione Charta   (Italy)

^c UNIVERSITY OF MILANO BICOCCA   (Italy)

^d G GASLINI INSTITUTE   (Italy)

^e UNIVERSITY OF PISA   (Italy)

^f UNIVERSITY OF NAPLES PARTHENOPE   (Italy)

^g UNIVERSITY OF NAPLES FEDERICO II   (Italy)

Author keywords

Cost effectiveness; Economic evaluation; Pharmacoeconomics; Quality of life; Rheumatology

Indexed keywords

TUMOR NECROSIS FACTOR ALPHA INHIBITOR;

ARTICLE; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; COST MINIMIZATION ANALYSIS; COST OF ILLNESS; COST UTILITY ANALYSIS; DRUG COST; ECONOMIC EVALUATION; HEALTH CARE COST; HEALTH CARE QUALITY; HOSPITALIZATION COST; HUMAN; OUTCOME ASSESSMENT; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; RHEUMATIC DISEASE; RHEUMATOID ARTHRITIS; SENSITIVITY ANALYSIS;

ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; COST-BENEFIT ANALYSIS; DRUG COSTS; ECONOMICS, PHARMACEUTICAL; HUMANS; RESEARCH DESIGN;

EID: 84870263002     PISSN: 0392856X     EISSN: 1593098X     Source Type: Journal    
DOI: None     Document Type: Article

References (66)

1. FURNERI G, MANTOVANI LG, BELISARI A et al.: Systematic literature review on economic implications and pharmacoeconomic issues of rheumatoid arthritis. Clin Exp Rheumatol 2012;30(Suppl.73):S72-S84.
2. CORTESI PA, SCALONE L, D'ANGIOLELLA L et al.: Systematic literature review on economic implications and pharmacoeconomic issues of psoriatic arthritis. Clin Exp Rheumatol 2012;30(Suppl.73):S126-S131.
3. MOSCA M, BOUMPAS D, BRUCE IN et al.: Treat-to-target in systemic lupus erythematosus: where are we today? Clin Exp Rheumatol 2012;30(Suppl.73):S112- S115.
4. TURCHETTI G, YAZDANY J, PALLA I, YELIN E, MOSCA M. Systemic lupus erythematosus and the economic perspective: a systematic literature review and points to consider. Clin Exp Rheumatol 2012;30(Suppl. 73):S116-S122.
5. PALLA I., TRIESTE L, TANI C et al.: A systematic literature review of the economic impact of ankylosing spondylitis. Clin Exp Rheumatol 2012;30(Suppl.73):S136-S141.
6. TRIESTE L, PALLA I, FUSCO F et al.: The economic impact of gout: systematic literature review. Clin Exp Rheumatol 2012;30(Suppl. 73):S145-S148.
7. TRIESTE L, PALLA I, BALDINI C et al.: Systemic vasculitis: how little we know about their societal and economic burden. Clin Exp Rheumatol 2012;30(Suppl. 73):S154-S156.
8. TURCHETTI, G, PALLA I, PIEROTTI F, CUSCHIERI A: Economic evaluation of da Vinci-assisted robotic surgery: a systematic review. Surgical Endoscopy 2012;26:598-606.
9. MANTOVAN I (Ed.), L'Health Technology Assessment. Principi, Concetti, Strumenti Operativi, II Sole 24ore Libri, Milano, 2011.
10. TURCHETTI, G, SPADONI E, GEISLER E: Health technology assessment. Evaluation of biomedical innovative technologies. IEEE Engineering in Medicine and Biology Magazine 2010;29:70-6.
11. KAVANAUGH A, COHEN S. CUSH J: The evolving use of TNF inhibitors in rheumatoid arthritis. J Rheumatol 2004;31:1881-4.
12. FAUTREL B: Economic benefits of optimizing anchor therapy for rheumatoid arthritis. Rheumatology 2012;51:iv21-iv26.
13. FAUTREL B, LUCIER S, LAROCHE ML et al.: Costs for early rheumatoid arthritis patients by type of treatments in France: results from the ESPOIR cohort. Ann Rheum Dis 2010;69(Suppl.3):351.
14. LUNDKVIST J, KASTANG F, KOBELT G: The burden of rheumatoid arthritis and access to treatment: health burden and costs. Eur J Health Econ 2008;8(Suppl. 2):S49-60.
15. KAVANAUGH A: Health economics: implications for novel antirheumatic therapy. Ann Rheum Dis 2005;64:iv65-iv69.
16. WONG J: Cost-effectiveness of anti-tumor necrosis factor agents. Clin Exp Rheumatol 2005;22(Suppl. 35):S65-S70.
17. CIMMINO M, LEARDINI G, SALAFFI F et al.: Assessing the cost-effectiveness of biologic agents for the management of moderate-tosevere rheumatoid arthritis in anti-TNF inadequate responders in Italy: a modelling approach. Clin Exp Rheumatol 2011;29:633-41.
18. MALHAN S, PAY S, ATAMAN S et al.: The cost of care of rheumatoid arthritis and ankylosing spondylitis patients in tertiary care rheumatology units in Turkey. Clin Exp Rheumatol 2012;30:202-7.
19. DRUMMOND M, SCULPHER MJ, TORRANCE GW, O'BRIEN BJ, STODDART GL: Methods for the Economic Evaluation of Health Care Programmes, 3rd ed. 2005; Oxford University Press: Oxford, UK.
20. HALLERT E, HUSBERG M, SKOGH T: Costs and course of disease and function in early rheumatoid arthritis: a 3-yearfollow-up (the Swedish TIRA project). Rheumatology 2006;45:325-31.
21. OLIVIERI I, DE PORTU S, SALVARANI C et al:, PACE WORKING GROUP: The psoriatic arthritis cost evaluation study: a cost-of-illness study on tumour necrosis factor inhibitors in psoriatic arthritis patients with inadequate response to conventional therapy. Rheumatology 2008;47:1664-70.
22. MERKESDAL S, RUOF J, HUELSEMANN JL et al.: Development of a matrix of cost domains in economic evaluation of rheumatoid arthritis. J Rheumatol 2001;28:657-61.
23. KOBELT G: Thoughts on health economics in rheumatoid arthritis. Ann Rheum Dis 2007;66(Suppl. 111):iii35-iii39.
24. NOBRE MR, DA COSTA FM: Surrogate outcomes are associated with low methodological quality of studies of rheumatoid arthritis treated with antitumour necrosis factor agents: a systematic review. Evid Based Med 2012;17:3-7.
25. WOODCOCK J, ATKINSON AJ JR, ROLAN P: Physiological and Laboratory Markers of Drug Effect. In: Principle of Clinical Pharmacology 3rd ed, (Eds. ATKINSON AJ Jr, HUANG S-M, LERTORA JJL and MARKEY SP) 309-25 (Academic Press, Burlington, San Diego, US, London, UK, 2012).
26. SOKKA T, KAUTIAINEN H, PINCUS T et al.: QUEST-RA: Work disability remains a major problem in rheumatoid arthritis in the 2000s: data from 32 countries in the QUEST-RA study. Arthritis Res Ther 2010;12:R42.
27. PUGNER KM, SCOTT DI, HOLMES JW, HIEKE K: The costs of rheumatoid arthritis: an international long-term view. Semin Arthritis Rheum 2000;29:305-20.
28. RAT AC, BOISSIER MC: Rheumatoid arthritis: direct and indirect costs. Joint Bone Spine 2004;71:518-24.
29. BURTON W, MORRISON A, MACLEAN R, RUDERMAN E: Systematic review of studies of productivity loss due to rheumatoid arthritis. Occup Med 2006;56:18-27.
30. KOOPMANSCHAP MA, RUTTEN FF, VAN INEVELD BM, VAN ROUEN L: The friction cost method for measuring indirect costs of disease. J Health Econ 1995;14:171-89.
31. LACAILLE D, WHITE MA, BACKMAN CL, GIGNAC MA: Problems faced at work due to inflammatory arthritis: new insights gained from understanding patients' perspective. Arthritis Rheum 2007;57:1269-79.
32. GARRATT A, SCHMIDT L, MACKINTOSH A, FITZPATRICK R: Quality of life measurement: bibliographic study of patient assessed health outcome measures. BMJ 2002;324:1417.
33. WHOQOL GROUP: Development of the WHOQOL: rationale and current status. Int J Mental Health 1994;23:24-8.
34. SULLIVAN M: The new subjective medicine: taking the patient's point of view on health care and health. Soc Sci Med 2003;56:1595-604.
35. GUYATT GH, FEENIY DH, PATRICK DL: Measuring health-related quality of life. Ann Intern Med 1993;118:622-9.
36. DOWIE J: Decision validity should determine whether a generic or a condition-specific HRQOL instrument is used in health care decisions. Health Econ 2002, 11;1-8 and commentaries on pages 9-22.
37. MEENAN R, GERTMAN P, MASON J, DUNAIF R: The arthritis impact measurement scale: further investigation of a health status measure. Arthritis Rheum 1982;25:1048-53.
38. WARE JE JR., SHERBOURNE CD: The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care 1992;30:473-83.
39. THE EUROQOL GROUP: EuroQol: a new facility for the measurement of health related quality of life. Health Policy 1990;16:199-208.
40. KOBELT G: Health economics: introduction to economic evaluation. London: Office of Health Economics, 1996.
41. DOLAN P, GUDEX C, KIND P, WILLIAMS A: A social tariff for EuroQol: Results from a UK general population survey. York: Centre for Health Economics, University of York, 1995. Discussion Paper 138.
42. TORRANCE G: Multi-attribute value and utility functions for a comprehensive health status classification system. Toronto: McMasters University, 1992.
43. TORRANCE G: Measurement of health state utilities for economic appraisal. J Health Econ 1986;5:1-30.
44. SCALONE L, TOMASETTO C, MATTEUCCI MC et al.: Assessing Quality of Life in Children and Adolescents: Development and Validation of the Italian Version of the EQ-5D-Y. Italian Journal of Public Health 2011;8:331-41.
45. WILLE N, BADIA X, BONSEL G et al.: Development of the EQ-5D-Y: a child-friendly version of the EQ-5D. Qual Life Res 2010;19:875-86.
46. RAVENS SIEBERER U, WILLE N, BADIA X et al.: Feasibility, reliability, and validity of the EQ-5D-Y: results from a multinational study. Qual Life Res 2010;19:887-97.
47. HERDMAN M, GUDEX C, LLOYD A et al.: Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L). Qual Life Res 2011;20:1727-36.
48. VAN HOUT B, JANSSEN MF, FENG YS et al.: Interim scoring for the EQ-5D-5L: mapping the EQ-5D-5L to EQ-5D-3L value sets. Value Health 2012;15:708-15.
49. YANG H, EPSTEIN D, BOJKE L et al.: Golimumab for the treatment of psoriatic arthritis. Health Technol Assess 2011;15(Suppl. 1):87-95.
50. MUGFORD M, KINGSTON J, CHALMERS I: Reducing the incidence of infection after caesarean section: implications of prophylaxis with antibiotics for hospital resources. BMJ 1989;299:1003-6.
51. BOJKE L, EPSTEIN D, CRAIG D et al.: Modelling the cost-effectiveness of biologic treatments for psoriatic arthritis. Rheumatology (Oxford) 2011;50(Suppl. 4):iv39-iv47.
52. BUXTON MJ, DRUMMOND MF, VAN HOUT BA et al.: Modelling in economic evaluation: an unavoidable fact of life? Health Econ 1997;6:217-27.
53. BRIGGS A, CLAXTON K, SCULPHER MJ: Decision Modelling for Health Economic Evaluation; Oxford University Press: Oxford, UK, 2006.
54. WEINSTEIN MC, O'BRIEN B, HORNBERGER J et al.: Principles of good practice for decision analytic modeling in health-care evaluation: report of the ISPOR Task Force on Good Research Practices - Modeling Studies. Value Health 2003;6:9-17.
55. JOBANPUTRA P: A clinician's critique of rheumatoid arthritis health economic models. Rheumatology (Oxford) 2011;50(Suppl. 4):iv48-iv52.
56. MERKESDAL S, RUOF J, HUELSEMANN JL et al.: Indirect cost assessment in patients with rheumatoid arthritis (RA): comparison of data from the health economic patient questionnaire HEQ-RA and insurance claims data. Arthritis Rheum 2005;53:234-40.
57. JACOBS P, YIM R: Using Canadian administrative databases to derive economic data for health technology assessments. Ottawa: Canadian Agency for Drugs and Technologies in Health; 2009.
58. WONG BJ, CIFALDI MA, ROY S, SKONIECZNY DC, STAVRAKAS S: Analysis of drug and administrative costs allowed by U. S. Private and public third-party payers for 3 intravenous biologic agents for rheumatoid arthritis. J Manag Care Pharm 2011;17:313-20.
59. BRIGGS A, SCULPHER M, BUXTON M: Uncertainty in the economic evaluation of health care technologies: the role of sensitivity analysis. Health Econ 1994;3:95-104.
60. NOSSENT J, KISS E, ROZMAN B et al.: Disease activity and damage accrual during the early disease course in a multinational inception cohort of patients with systemic lupus erythematosus. Lupus 2010;19:949-56.
61. FRANKE LC, AMENT AJ, VAN DE LAAR MA, BOONEN A, SEVERENS JL: Cost-of-illness of rheumatoid arthritis and ankylosing spondylitis. Clin Exp Rheumatol 2009;27(Suppl. 55):S118-23.
62. PEARCE D: Cost-Benefit analysis and environmental policy. Oxford Review of Economic Policy 1998;14:84-100.
63. RYAN, M, WATSON V, AMAYA-AMAYA M: Methodological issues in the monetary valuation of benefits in healthcare. Expert Rev Pharmacoecon Outcomes Res 2003;3:717-27.
64. WEINSTEIN MC, STASON WB: Foundations of Cost-Effectiveness Analysis for Health and Medical Practices. N Engl J Med 1977;296:716-21.
65. TURCHETTI G: L'Health Technology Assessment. Riflessioni sulla dimensione e sulle implicazioni organizzative, In: MANTOVANI L. (Ed.), L'Health Technology Assessment. Principi, Concetti, Strumenti Operativi, II Sole 24ore Libri, Milano, 2011.
66. MOSCA M, TANI C, ARINGER M et al.: Development of quality indicators to evaluate the monitoring of SLE patients in routine clinical practice. Autoimmun Rev 2011;10:383-8.